MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) announced that Larry Jasinski, Chief Executive Officer, will present and host one-on-one meetings with investors virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023.
The presentation will be available via webcast on Monday, September 11, 2023 starting at 7:00 AM EDT and can be accessed by clicking here. ReWalk will also post this link on the Investors section of our website at rewalk.com where it will be available on-demand for 90 days.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. Alter G® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.
| ReWalk Investor Contact: Mike Lawless Chief Financial Officer ReWalk Robotics E: This email address is being protected from spambots. You need JavaScript enabled to view it. | ReWalk Media Relations: John Tomlin E: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.50 |
| Daily Change: | 0.01 0.67 |
| Daily Volume: | 64,719 |
| Market Cap: | US$13.220M |
November 12, 2024 October 24, 2024 September 24, 2024 September 04, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
